interferon - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.91 [0.25, 3.29]< 151%4 studies (4/-)56.0 %some concernnot evaluable moderatecrucial-
deaths 0.85 [0.62, 1.18]< 123%14 studies (14/-)82.8 %some concerncritical moderatecrucial-
deaths (time to event analysis only) 0.76 [0.17, 3.38]< 175%2 studies (2/-)64.3 %highnot evaluable lowcrucial-
clinical deterioration 0.67 [0.44, 1.03]< 10%4 studies (4/-)96.6 %NAnot evaluable important-
clinical improvement 1.36 [1.01, 1.82]> 161%7 studies (7/-)97.8 %some concernserious moderateimportant-
clinical improvement (14-day) 1.54 [0.69, 3.39]> 168%4 studies (4/-)85.5 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 3.42 [1.70, 6.88]> 10%2 studies (2/-)100.0 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.90 [1.07, 3.35]> 10%2 studies (2/-)98.6 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.30 [1.03, 1.63]> 160%8 studies (8/-)98.8 %some concernserious moderateimportant-
death or ventilation 1.00 [0.79, 1.26]< 19%3 studies (3/-)50.7 %some concernnot evaluable moderateimportant-
hospital discharge 1.31 [0.88, 1.94]> 125%4 studies (4/-)90.6 %lownot evaluable highimportant-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %NAnot evaluable important-
mechanical ventilation 0.73 [0.40, 1.32]< 10%5 studies (5/-)85.3 %some concernnot evaluable moderateimportant-
Recovery (time to event analysis only) 1.02 [0.81, 1.28]> 10%1 study (1/-)56.7 %NAnot evaluable important-
viral clearance 2.21 [0.98, 5.02]> 180%5 studies (5/-)97.1 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 1.57 [0.74, 3.34]> 185%3 studies (3/-)88.2 %some concernnot evaluable moderateimportant-
viral clearance by day 14 0.71 [0.01, 43.06]> 197%4 studies (4/-)43.7 %some concernnot evaluable moderateimportant-
viral clearance by day 7 2.60 [1.67, 4.05]> 10%4 studies (4/-)100.0 %some concernnot evaluable moderateimportant-
ICU admission 0.49 [0.24, 1.00]< 10%3 studies (3/-)97.4 %some concernnot evaluable moderatenon important-
off oxygenation 8.57 [1.43, 51.36]> 10%1 study (1/-)99.0 %NAnot evaluable non important-
recovery 2.19 [1.03, 4.67]> 10%1 study (1/-)97.9 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.99 [0.17, 5.88]< 10%2 studies (2/-)50.5 %some concernnot evaluable moderateimportant-
superinfection 0.77 [0.06, 9.89]< 176%2 studies (2/-)57.8 %highnot evaluable lowimportant-
adverse events 1.39 [0.80, 2.40]< 10%3 studies (3/-)12.1 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.